Overview

Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonate Alone

Status:
Completed
Trial end date:
2009-09-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated concentration (MTC) of bisphosphonate with a fixed dose of rHuPH20 administered SC, the MTC of bisphosphonate without rHuPH20 administered SC, the optimal dose of rHuPH20 to deliver bisphosphonate SC at MTC, and to compare the PK of SC administered bisphosphonate at MTC with optimal dose rHuPH20 to bisphosphonate alone.
Phase:
Phase 1
Details
Lead Sponsor:
Halozyme Therapeutics
Treatments:
Diphosphonates
Zoledronic Acid